share_log

Grail | 8-K: Current report

Grail | 8-K: Current report

Grail | 8-K:重大事件
美股SEC公告 ·  01/15 17:03

牛牛AI助理已提取核心訊息

Grail announced preliminary FY2024 results, reporting total revenue of $124-126M, with US Galleri revenue reaching $107-110M. The company sold approximately 137,000 Galleri cancer detection tests in 2024, with over 13,000 ordering providers and a 20% repeat order rate. The company maintains a strong cash position of $767M as of December 31, 2024, providing runway into 2028.The company launched a new version of Galleri in December 2024, demonstrating consistent performance with 43-44% positive predictive value across studies. Grail's commercial infrastructure includes 170,000 sq ft of CAP-accredited, CLIA-certified lab facilities with capacity to support multiple years of growth. The company has processed over 600,000 clinical and commercial tests to date.Looking ahead, Grail projects 20-30% growth in US Galleri sales for 2025 with projected cash burn below $320M. Key upcoming catalysts include registrational trial data from PATHFINDER 2 and NHS studies, with plans to complete modular PMA submission to FDA in 1H 2026.
Grail announced preliminary FY2024 results, reporting total revenue of $124-126M, with US Galleri revenue reaching $107-110M. The company sold approximately 137,000 Galleri cancer detection tests in 2024, with over 13,000 ordering providers and a 20% repeat order rate. The company maintains a strong cash position of $767M as of December 31, 2024, providing runway into 2028.The company launched a new version of Galleri in December 2024, demonstrating consistent performance with 43-44% positive predictive value across studies. Grail's commercial infrastructure includes 170,000 sq ft of CAP-accredited, CLIA-certified lab facilities with capacity to support multiple years of growth. The company has processed over 600,000 clinical and commercial tests to date.Looking ahead, Grail projects 20-30% growth in US Galleri sales for 2025 with projected cash burn below $320M. Key upcoming catalysts include registrational trial data from PATHFINDER 2 and NHS studies, with plans to complete modular PMA submission to FDA in 1H 2026.
Grail公司發佈了2024財年的初步業績,報告總營業收入爲12400-12600萬,其中美國Galleri的營業收入達到10700-11000萬。2024年,該公司銷售了約137,000個Galleri癌症檢測測試,擁有超過13,000個訂購提供者,復購率爲20%。截至2024年12月31日,該公司保持了強勁的現金狀況,現金儲備爲76700萬,能夠支持到2028年。該公司在2024年12月推出了新版本的Galleri,顯示出在各研究中一致的表現,陽性預測值爲43-44%。Grail的商業基礎設施包括170,000平方英尺的CAP認證、CLIA認證的實驗室設施,具備支持多年增長的能力。至今,該...展開全部
Grail公司發佈了2024財年的初步業績,報告總營業收入爲12400-12600萬,其中美國Galleri的營業收入達到10700-11000萬。2024年,該公司銷售了約137,000個Galleri癌症檢測測試,擁有超過13,000個訂購提供者,復購率爲20%。截至2024年12月31日,該公司保持了強勁的現金狀況,現金儲備爲76700萬,能夠支持到2028年。該公司在2024年12月推出了新版本的Galleri,顯示出在各研究中一致的表現,陽性預測值爲43-44%。Grail的商業基礎設施包括170,000平方英尺的CAP認證、CLIA認證的實驗室設施,具備支持多年增長的能力。至今,該公司已處理超過600,000個臨牀和商業測試。展望未來,Grail預計2025年美國Galleri的銷售將增長20-30%,預計現金消耗低於32000萬。即將發佈的關鍵催化劑包括PATHFINDER 2和NHS研究的註冊試驗數據,計劃在2026年上半年完成模塊化PMA向FDA提交。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 297

熱點推薦

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。